Cited 318 times in
Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: Pooled analyses after long-term follow-up in KEYNOTE-012
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 정현철 | - |
dc.date.accessioned | 2018-09-28T08:52:34Z | - |
dc.date.available | 2018-09-28T08:52:34Z | - |
dc.date.issued | 2018 | - |
dc.identifier.issn | 0007-0920 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/163180 | - |
dc.description.abstract | BACKGROUND: Second-line treatment options for advanced head and neck squamous cell carcinoma (HNSCC) are limited. The phase Ib KEYNOTE-012 study evaluated the safety and the efficacy of pembrolizumab for the treatment of HNSCC after long-term follow-up. METHODS: Multi-centre, non-randomised trial included two HNSCC cohorts (initial and expansion) in which 192 patients were eligible. Patients received pembrolizumab 10 mg/kg every 2 weeks (initial cohort; N = 60) or 200 mg every 3 weeks (expansion cohort; N = 132). Co-primary endpoints were safety and overall response rate (ORR; RECIST v1.1; central imaging vendor review). RESULTS: Median follow-up was 9 months (range, 0.2-32). Treatment-related adverse events (AEs) of any grade and grade 3/4 occurred in 123 (64%) and 24 (13%) patients, respectively. No deaths were attributed to treatment-related AEs. ORR was 18% (34/192; 95% CI, 13-24%). Median response duration was not reached (range, 2+ to 30+ months); 85% of responses lasted ≥6 months. Overall survival at 12 months was 38%. CONCLUSIONS: Some patients received 2 years of treatment and the responses were ongoing for more than 30 months; the durable anti-tumour activity and tolerable safety profile, observed with long-term follow-up, support the use of pembrolizumab as a treatment for recurrent/metastatic HNSCC. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Nature Publishing Group on behalf of Cancer Research UK | - |
dc.relation.isPartOf | BRITISH JOURNAL OF CANCER | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.title | Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: Pooled analyses after long-term follow-up in KEYNOTE-012 | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Internal Medicine | - |
dc.contributor.googleauthor | Ranee Mehra | - |
dc.contributor.googleauthor | Tanguy Y. Seiwert | - |
dc.contributor.googleauthor | Shilpa Gupta | - |
dc.contributor.googleauthor | Jared Weiss | - |
dc.contributor.googleauthor | Iris Gluck | - |
dc.contributor.googleauthor | Joseph P. Eder | - |
dc.contributor.googleauthor | Barbara Burtness | - |
dc.contributor.googleauthor | Makoto Tahara | - |
dc.contributor.googleauthor | Bhumsuk Keam | - |
dc.contributor.googleauthor | Hyunseok Kang | - |
dc.contributor.googleauthor | Kei Muro | - |
dc.contributor.googleauthor | Ravit Geva | - |
dc.contributor.googleauthor | Hyun Cheol Chung | - |
dc.contributor.googleauthor | Chia-Chi Lin | - |
dc.contributor.googleauthor | Deepti Aurora-Garg | - |
dc.contributor.googleauthor | Archana Ray | - |
dc.contributor.googleauthor | Kumudu Pathiraja | - |
dc.contributor.googleauthor | Jonathan Cheng | - |
dc.contributor.googleauthor | Laura Q. M. Chow | - |
dc.contributor.googleauthor | Robert Haddad | - |
dc.identifier.doi | 10.1038/s41416-018-0131-9 | - |
dc.contributor.localId | A03773 | - |
dc.relation.journalcode | J00406 | - |
dc.identifier.eissn | 1532-1827 | - |
dc.identifier.pmid | 29955135 | - |
dc.identifier.url | http://www.nature.com/articles/s41416-018-0131-9 | - |
dc.contributor.alternativeName | Chung, Hyun Cheol | - |
dc.contributor.affiliatedAuthor | Chung, Hyun Cheol | - |
dc.citation.volume | 119 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 153 | - |
dc.citation.endPage | 159 | - |
dc.identifier.bibliographicCitation | BRITISH JOURNAL OF CANCER, Vol.119(2) : 153-159, 2018 | - |
dc.identifier.rimsid | 58448 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.